Latest Breaking News On - Yannick tetzlaff - Page 6 : vimarsana.com
INVENTIVA: Inventiva announces the implementation of an At-The-Market program in the United States
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Investegate |INVENTIVA Announcements | INVENTIVA: Inventiva Reports First-Half of 2021 Financial Information
investegate.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investegate.co.uk Daily Mail and Mail on Sunday newspapers.
INVENTIVA: Inventiva to participate at the SVB Leerink CybeRx Series: Liver Disease Day
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Investegate |INVENTIVA Announcements | INVENTIVA: Inventiva to participate at the SVB Leerink CybeRx Series: Liver Disease Day
investegate.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investegate.co.uk Daily Mail and Mail on Sunday newspapers.
INVENTIVA: Inventiva announces three scientific presentations at the EASL International Liver Congress 2021 and during a KOL webcast event
the beneficial effects of lanifibranor on cardiovascular risk biomarkers in patients with NASH
the positive effects of lanifibranor on several biomarkers of disease activity and associated risks in patients with NASH and F2/F3 fibrosis
One poster presentation showing the beneficial effects of the combination treatment of lanifibranor and ACC1/2 inhibitor firsocostat from Gilead
Inventiva will host a dedicated Key Opinion Leader (KOL) webcast event for investors and analysts on June 29, 2021
Daix (France), June 9, 2021 - Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS) and other diseases with significant unmet medical need, today announced that three abstracts